Humanigen, Inc. (HGEN): Price and Financial Metrics

Humanigen, Inc. (HGEN): $0.00

0.00 (-84.62%)

POWR Rating

Component Grades








Add HGEN to Watchlist
Sign Up

Industry: Biotech




#148 of 401

in industry

HGEN Price/Volume Stats

Current price $0.00 52-week high $0.24
Prev. close $0.00 52-week low $0.00
Day low $0.00 Volume 2,063,600
Day high $0.00 Avg. volume 3,262,400
50-day MA $0.00 Dividend yield N/A
200-day MA $0.07 Market Cap 23.82K

HGEN Stock Price Chart Interactive Chart >

Humanigen, Inc. (HGEN) Company Bio

Humanigen, Inc., a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.

HGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

HGEN Latest Social Stream

Loading social stream, please wait...

View Full HGEN Social Stream

Latest HGEN News From Around the Web

Below are the latest news stories about HUMANIGEN INC that investors may wish to consider to help them evaluate HGEN as an investment opportunity.

Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress

Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon previously reported positive clinical responses, these additional data demonstrate statistically significant and clinically relevant improvements in hematologic outcomes, along with improvements in inflammatory markers, that occur in the early months after treatment initiation and appear durableCMML

Yahoo | June 9, 2023

Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia

CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab and with current standard of care, azacitidineSix evaluable subjects, including those with high risk CMML, demonstrated clinical benefit at three months follow-upLenzilumab appears to be well-toleratedShort Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - April 14, 2023) - Humanigen, Inc. (Nasdaq: HGEN), Humanigen Australia Pty L

Yahoo | April 14, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for trader need to kno about Wednesday!

William White on InvestorPlace | February 15, 2023

Humanigen Reports Third Quarter 2022 Financial Results

Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the third quarter and nine months ended September 30, 2022.In July 2022, the company announced a strategic realignment of its pipeline, resources and regulatory strateg

Yahoo | November 14, 2022

Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced that Cameron Durrant, MD, MBA, Chairman & CEO, will give a corporate presentation at 11:25am EST (4:25pm local time) at the Jefferies London Healthcare Conference taking place on November 17, 2022. Dr. Durrant will provide an update on the clinica

Yahoo | November 10, 2022

Read More 'HGEN' Stories Here

HGEN Price Returns

1-mo N/A
3-mo N/A
6-mo 0.00%
1-year 0.00%
3-year 0.00%
5-year 0.00%
YTD 0.00%
2023 -99.00%
2022 -96.77%
2021 -78.74%
2020 617.95%
2019 -30.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!